The Roche group has made regulatory submissions in the US and Europe for vemurafenib, a new drug to treat metastatic melanoma, together with a diagnostic test that would identify people with tumours carrying a specific genetic mutation. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy
